Skip to content
AnalystLens

Charles River Laboratories International 8-K Report, Financial Results (Nov 6, 2024)

Reports
Earnings & Results·Exhibits & Filings
Filing Date
Filed November 6, 2024
Period End
November 6, 2024
Security
CRL
In the record · 2016–202610-K1110-Q338-K117

CRL filed 11 annual reports (10-K), 33 quarterly reports (10-Q) and 117 current reports (8-K) between 2016 and 2026.

  1. Deal closed8-K · Apr ’18Apr ’18
  2. Material agreement8-K · Oct ’19Oct ’19
  3. Leadership change8-K · Mar ’22Mar ’22
  4. Leadership change8-K · May ’26May ’26

Summary

Summary of the 8-K filed November 6, 2024. Cited figures are marked; the original filing is the authoritative source.

Charles River Laboratories International, Inc. reported third-quarter 2024 results for the quarter ended September 28, 2024.

Revenue was $1.01 billiona, a decrease of 1.6% from $1.03 billion a year earlier, or a 2.7% decline on an organic basis. GAAP diluted earnings per share were $1.33, compared with $1.69 in the third quarter of 2023, while non-GAAP diluted earnings per share were $2.59, compared with $2.72. The GAAP operating margin fell to 11.6% from 14.8%, mainly due to restructuring costs, and the non-GAAP operating margin declined to 19.9% from 20.5%, as improvements in all three segments were offset by higher unallocated corporate costs.

Segment results were mixed. Research Models and Services revenue rose 5.9% to $197.8 millionb, aided by the Noveprim acquisition, and Manufacturing Solutions revenue rose 12.0% to $196.9 million, with organic growth of 11.8%. Discovery and Safety Assessment revenue fell 7.4% to $615.1 million, driven by lower volume in both Discovery Services and Safety Assessment.

Management said demand indicators were relatively stable in the quarter and that biotech funding had improved in 2024, though clients are still reducing spending during restructuring and pipeline reprioritization. The company narrowed and slightly raised its non-GAAP EPS guidance to $10.10 to $10.30c and lowered its GAAP EPS guidance to $5.30 to $5.50.

Reported revenue growth guidance is now (3.0)% to (2.0)%. The company also authorized a new $1.0 billiond stock repurchase program in August 2024, repurchased $100.7 million of shares in the third quarter, and had $899.3 million remaining under that authorization as of September 28, 2024.

Key Highlights

  1. Third-quarter revenue of $1.01 billion, down 1.6% year over year; organic revenue declined 2.7%.
  2. GAAP diluted EPS of $1.33 versus $1.69 a year earlier; non-GAAP diluted EPS of $2.59 versus $2.72.
  3. GAAP operating margin fell to 11.6% from 14.8%, driven mainly by restructuring costs; non-GAAP operating margin was 19.9% versus 20.5%.
  4. Discovery and Safety Assessment revenue fell 7.4% to $615.1 million, while Manufacturing Solutions grew 12.0% to $196.9 million and Research Models and Services grew 5.9% to $197.8 million.
  5. 2024 non-GAAP EPS guidance narrowed and slightly raised to $10.10–$10.30; GAAP EPS guidance reduced to $5.30–$5.50 due to additional restructuring charges.
  6. Reported revenue growth guidance for 2024 is (3.0)% to (2.0)%, versus the prior (4.5)% to (2.5)%.
  7. A new $1.0 billion stock repurchase authorization approved August 2, 2024; $100.7 million repurchased in the third quarter, leaving $899.3 million remaining.

Frequently Asked Questions

  1. Why did GAAP earnings decline more sharply than non-GAAP earnings?

    GAAP results were pressured by higher costs tied to the company's restructuring initiatives, including severance and site consolidation charges. Non-GAAP results exclude many of these items, so the GAAP EPS decline of 21.3% was steeper than the 4.8% non-GAAP decline.

  2. How did the segments perform?

    Manufacturing Solutions led with 12.0% revenue growth and an 11.8% organic increase, and Research Models and Services rose 5.9%, helped by the Noveprim acquisition and higher small research model pricing. Discovery and Safety Assessment revenue fell 7.4%, driven by lower volume in Discovery Services and Safety Assessment.

  3. What changed in the 2024 guidance?

    Non-GAAP EPS guidance was narrowed and slightly raised to $10.10–$10.30 from $9.90–$10.20 to reflect third-quarter performance above the company's prior outlook. GAAP EPS guidance was lowered to $5.30–$5.50 from $5.65–$5.95 because of increased restructuring charges, which are now estimated at about $1.50 per share versus about $1.00 previously.

  4. What did management say about client demand?

    Chair, President and CEO James C. Foster said forward-looking demand indicators were relatively stable in the third quarter, with biotech funding improving in 2024 and early signs of stabilization. He added that clients are still reducing spending amid major restructuring and pipeline reprioritization, and that net book-to-bill and the cancellation rate improved slightly sequentially in Safety Assessment.

  5. How much capital has the company returned to shareholders?

    The company repurchased 500,000 shares in the third quarter for $100.7 million under its new $1.0 billion authorization, leaving $899.3 million available as of September 28, 2024. Cash flow statements for the nine months show purchases of treasury stock of $119.1 million.